Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

PROCEPT BioRobotics (PRCT) Operating Expenses (2020 - 2026)

PROCEPT BioRobotics has reported Operating Expenses over the past 7 years, most recently at $86.6 million for Q1 2026.

  • Quarterly Operating Expenses rose 20.89% to $86.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $315.0 million through Mar 2026, up 24.7% year-over-year, with the annual reading at $300.1 million for FY2025, 28.4% up from the prior year.
  • Operating Expenses was $86.6 million for Q1 2026 at PROCEPT BioRobotics, up from $77.4 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $86.6 million in Q1 2026 and troughed at $23.4 million in Q1 2022.
  • The 5-year median for Operating Expenses is $52.7 million (2024), against an average of $54.0 million.
  • Year-over-year, Operating Expenses soared 89.8% in 2022 and then rose 20.89% in 2026.
  • A 5-year view of Operating Expenses shows it stood at $35.7 million in 2022, then surged by 42.27% to $50.8 million in 2023, then rose by 24.74% to $63.4 million in 2024, then grew by 22.04% to $77.4 million in 2025, then rose by 11.89% to $86.6 million in 2026.
  • Per Business Quant, the three most recent readings for PRCT's Operating Expenses are $86.6 million (Q1 2026), $77.4 million (Q4 2025), and $77.2 million (Q3 2025).